At the WIRED Health summit last week, Harvard biochemist and gene-editing pioneer David Liu said that later this year his lab plans to report on a single gene-editing strategy that could treat many unrelated diseases. He calls it disease-agnostic therapeutic gene editing.
“It sounds sort of crazy, but there’s actually a very good molecular biology reason why this could be possible,” he told the audience in Boston, stopping short of details.
Gene-editing treatments are currently being developed for several rare and inherited genetic diseases. One gene-editing treatment, called Casgevy, is approved and available commercially to treat sickle cell disease and a related blood disorder called beta thalassemia. Earlier this year, KJ